227 related articles for article (PubMed ID: 15257072)
21. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
[TBL] [Abstract][Full Text] [Related]
22. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
[TBL] [Abstract][Full Text] [Related]
24. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
25. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
26. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
27. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
29. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
[TBL] [Abstract][Full Text] [Related]
30. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of C2 monitoring in Korean renal transplantation.
Park JB; Han YS; Kim SJ; Choi GS; Kwon CH; Lee SK; Kim DJ; Joh JW
Transplant Proc; 2007 Dec; 39(10):3105-8. PubMed ID: 18089332
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
33. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy.
Filler G
Transpl Int; 2004 Mar; 17(3):120-5. PubMed ID: 14749919
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
35. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.
Pillans PI; Rigby RJ; Kubler P; Willis C; Salm P; Tett SE; Taylor PJ
Clin Biochem; 2001 Feb; 34(1):77-81. PubMed ID: 11239520
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
[TBL] [Abstract][Full Text] [Related]
37. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
38. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
Kahan BD; Welsh M; Schoenberg L; Rutzky LP; Katz SM; Urbauer DL; Van Buren CT
Transplantation; 1996 Sep; 62(5):599-606. PubMed ID: 8830822
[TBL] [Abstract][Full Text] [Related]
39. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation.
Meier-Kriesche HU; Kaplan B; Brannan P; Kahan BD; Portman RJ
Ther Drug Monit; 1998 Aug; 20(4):401-7. PubMed ID: 9712465
[TBL] [Abstract][Full Text] [Related]
40. Improving the therapeutic monitoring of cyclosporin A.
Warrens AN; Waters JB; Salama AD; Lechler RI
Clin Transplant; 1999 Apr; 13(2):193-200. PubMed ID: 10202617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]